Understanding how the immune system can fight brain tumors in patients with specific genetic mutations.
Interrogating Mechanisms of Anti-tumor Immunity in Human Subjects and Murine Models of IDH-Mutant Glioma Treated with All-Trans Retinoic Acid and PD-1 Inhibition
This study is looking at how the immune system works with a specific type of brain tumor called IDH-mutant gliomas and testing if certain treatments can help boost the body's ability to fight these tumors, with the goal of finding better, personalized treatment options for patients.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10880594 on NIH RePORTER |
What this research studies
This research investigates how the immune system interacts with IDH-mutant gliomas, a type of brain tumor, and how treatments like All-Trans Retinoic Acid and PD-1 inhibitors can enhance anti-tumor immunity. By analyzing both human clinical trial data and mouse models, the researchers aim to identify immune biomarkers and key immune cell types that can predict how well these tumors respond to therapy. This approach could lead to more effective treatment strategies tailored to individual patients based on their tumor's characteristics.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with IDH-mutant gliomas who are seeking new treatment options.
Not a fit: Patients with gliomas that do not have IDH mutations or those who are not eligible for immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for patients with IDH-mutant gliomas, potentially increasing survival rates and quality of life.
How similar studies have performed: Previous research has shown promise in using immunotherapy for brain tumors, but this specific approach focusing on IDH mutations and combined therapies is relatively novel.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Amankulor, Nduka Mgbechinyere — University of Pennsylvania
- Study coordinator: Amankulor, Nduka Mgbechinyere
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.